| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 6. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | eftrenonacog alfa (Alprolix®) |
| Formulation | 250 IU, 500 IU, 1000 IU, 2000 IU and 3000 IU powder and solvent for solution for injection |
| Reference number | 1875 |
| Indication | Treatment and prophylaxis of bleeding in patients with Haemophilia B (congenital factor IX deficiency) |
| Company | Swedish Orphan Biovitrum Ltd |
| BNF chapter | Cardiovascular system |
| Submission type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 11/04/2016 |